No Data
No Data
No Data
No Data
No Data
HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals with a Buy and maintains $92 price target.
Analyst UpgradesApr 27 02:22
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential
TipRanksApr 26 23:45
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apellis Pharmaceuticals (APLS) said Friday that the review of the marketing authorization application for pegcetacoplan has been reset to day 180, the last phase of the initial assessment by the Europ
MT NewswiresApr 26 22:30
Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment.
Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment.
BenzingaApr 26 19:22
European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates An Opinion From CHMP No Later Than July 2024
European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates
BenzingaApr 26 19:19
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
TipRanksApr 26 15:08
No Data
No Data